Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate
Brivanib alaninate is a prodrug of brivanib (BMS-540215), a potent oral VEGFR-2 inhibitor and is currently in development for the treatment of hepatocellular and colon carcinomas. In vitro and in vivo studies were conducted to characterize the preclinical pharmacokinetics and disposition of brivanib and brivanib alaninate, and antitumor efficacy in mice bearing human xenografts.
In vitro studies were conducted in liver and intestinal fractions, plasma and Caco-2 cells to assess the metabolic stability. Pharmacokinetics of brivanib were determined in preclinical species after administration of single intravenous or oral doses of both brivanib and brivanib alaninate. The antitumor efficacy was assessed at equimolar doses in nude mice bearing human tumor xenografts. Human efficacious dose was predicted based on projected human pharmacokinetic parameters and exposure at efficacious doses in the mouse efficacy models.
In vitro and in vivo studies indicated that brivanib alaninate was efficiently converted to brivanib. Brivanib showed good brain penetration in rats consistent with its high intrinsic permeability and lack of active efflux in Caco-2 cells. The oral bioavailability of brivanib varied among species (22–88%) and showed dissolution rate-limited absorption even when combined with organic co-solvents. Administration of brivanib as brivanib alaninate allowed completely aqueous vehicles, and an improvement in the oral bioavailability (55–97%) was observed. The clearance of brivanib in humans is anticipated to be low to intermediate (hepatic extraction ratio < 0.7), while its volume of distribution is expected to be high. The minimum efficacious dose of brivanib alaninate was determined to be 60 mg/kg per day.
Brivanib alaninate is rapidly and efficiently converted to the parent, brivanib, as demonstrated both in vitro and in vivo and offers an excellent mode to deliver brivanib orally.
KeywordsBMS-540215 Brivanib alaninate Prodrug Pharmacokinetics Oral bioavailability
We would like to thank Anthony Marino and Melissa Yarde for conducting the Caco-2 experiments, George Derbin for formulation support, Carl Davies for reaction phenotyping studies, and R. M. Fancher and the technical services unit for their help with all in vivo studies.
- 3.Berry M, Edwards AM, Barritt GJ (1991) Isolated hepatocytes preparation, properties and applications in laboratory techniques in biochemistry and molecular biology. Elsevier, AmsterdamGoogle Scholar
- 4.Bhide RS, Cai ZW, Zhang YZ, Qian L, Wei D, Barbosa S, Lombardo LJ, Borzilleri RM, Zheng X, Wu LI, Barrish JC, Kim SH, Leavitt K, Mathur A, Leith L, Chao S, Wautlet B, Mortillo S, Jeyaseelan R Sr, Kukral D, Hunt JT, Kamath A, Fura A, Vyas V, Marathe P, D’Arienzo C, Derbin G, Fargnoli J (2006) Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2, 1-f][1, 2, 4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem 49:2143–2146PubMedCrossRefGoogle Scholar
- 5.Cai ZW, Zhang Y, Borzilleri RM, Qian L, Barbosa S, Wei D, Zheng X, Wu L, Fan J, Shi Z, Wautlet BS, Mortillo S, Jeyaseelan R Sr, Kukral DW, Kamath A, Marathe P, D’Arienzo C, Derbin G, Barrish JC, Robl JA, Hunt JT, Lombardo LJ, Fargnoli J, Bhide RS (2008) Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2, 1-f] [1, 2, 4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem 51:1976–1980PubMedCrossRefGoogle Scholar
- 7.Corbett T (1997) In vivo methods for screening and preclinical testing. Humana Press Inc, TotowaGoogle Scholar
- 9.de Mulder PH, Haanen JB, Sleijfer S, Kruit WH, Gietema JA, Richel DJ, Groenewegen G, Voest EE, van den Eertwegh AJ, Osanto S, Jansen RL, Mulders PF (2008) Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus. Ned Tijdschr Geneeskd 152:371–375PubMedGoogle Scholar
- 11.Eric Masson AR, Kollia G, Syed S, Feltquate D, Mokliatchouk O, Velasquez L, Jonker D, Jayson G, Galbraith S (2008) Pharmacokinetics and pharmacodynamics of brivanib alaninate (BMS-582664), an oral dual inhibitor of VEGFR and FGFR signalliing pathways in patients with advanced/metastatic solid tumors. 9th World Conference on Clinical Pharmacology and Therapeutics, Quebec, CanadaGoogle Scholar
- 14.Gibaldi M, Perrier D (1982) Pharmacokinetics. Marcel-Dekker, New YorkGoogle Scholar